

PT Medco Energi Internasional Tbk

BUY

Last Price **1340**

Target Price **2000-2200**

Upside **+56.72%**

Source: IDX, Profindo Research

COMPANY INFO

Ticker	MEDC
52W Range	875-1750
YTD Return	27.27%
JCI	13.86%
Share Out.	25.1bn
Market Cap	35.9tn
Sector	Energy

Source: Company, IDX, Reuters

SHAREHOLDER

Company	74.78%
Public	25.22%

Source: Company

HIGHLIGHT

in US\$mn 2024

Assets	7,926.9
Liabilities	5,575.9
Equity	2,351.0

Revenue	2,399.2
Gross Profit	933.5
Net Profit	380.2

NPM	16%
PER	10.61
PBV	0.92

Source: Company, IDX

PRICE (5Y)



Source: Reuters

Research Analyst:

Darmawan Putra Wijaya

darmawan.putra@profindo.com

Pengambilalihan blok minyak dan gas Sumatra Selatan dari Repsol

MEDC telah setuju untuk membeli dua blok minyak dan gas di Sumatra Selatan dari Repsol, senilai sekitar US\$90 juta. MEDC akan mengakuisisi 45% kepemilikan di blok Sakakemang dan 80% kepemilikan di South Sakakemang. Transaksi ini diestimasi akan menghasilkan EBITDA sebesar 4.47% atau US\$30 juta lebih besar dari tahun 2024. Selanjutnya, MEDC akan mengambilalih peran sebagai operator, tergantung pada persetujuan pemerintah.

Memperoleh pinjaman dari bank asing

Dua anak usaha MEDC mendapat pinjaman sebesar US\$500 juta dari beberapa bank asing. MEDC melakukan penandatanganan perjanjian kredit melalui Medco E&P Grissik Ltd. dan Far East Energy Trading Pte. Ltd pada 26 Juni 2025. Pada tahun 2024, MEDC memperoleh peningkatan rating kredit menjadi BB-. MEDC melaporkan tingkat bunga pinjaman sebesar 4,16% hingga 8,44% pada tahun 2025. Transaksi dilaksanakan sebagai bagian dari strategi pendanaan jangka menengah grup MEDC. Bank kreditur antara lain, Australia and New Zealand Banking Group Limited Singapore Branch, ING Bank N.V. Singapore Branch, MUFG Bank Ltd. dan Standard Chartered Bank (Singapore) Limited.

Penandatanganan perjanjian swap gas domestik multi-pihak

MEDC melalui anak usahanya Medco E&P Natuna Ltd. dan Medco E&P Grissik Ltd., telah melakukan penandatanganan perjanjian *gas swap* domestik. Adapun, Medco E&P Natuna Ltd. yang tergabung dalam West Natuna Group Supply Group. Ada juga, Medco E&P Grissik Ltd. sebagai salah satu pemasok gas kepada Gas Supply Pte Ltd. dari Blok Corridor dan PSC Jabung (South Sumatra Sellers). Pemberlakuan swap gas ini untuk peningkatan efisiensi melalui pemotongan biaya, waktu, dan jarak transportasi gas. Peningkatan efisiensi bisa terjadi pada rentang 5% hingga 15%.

Pembagian dividen interim

PT Medco Energi Internasional Tbk (MEDC) membagikan dividen interim senilai US\$42 juta atau sekitar IDR698 miliar untuk tahun buku 2025. Dividen interim setara dengan Rp28,3 per saham yang memberikan *yield rate* sebesar 1.98%. Tanggal-tanggal penting untuk pembagian dividen adalah sebagai berikut:

- 10 November 2025 : Cum Dividen di Pasar Reguler dan Negosiasi
- 11 November 2025 : Ex Dividen di Pasar Reguler dan Negosiasi
- 12 November 2025 : Cum Dividen di Pasar Tunai
- 13 November 2025 : Ex Dividen di Pasar Tunai
- 28 November 2025 : Pembagian Dividen Interim

Valuasi

Saham MEDC diperdagangkan pada harga Rp1.340,00 per saham. PER MEDC saat ini sebesar 10,6x dengan PER subsektor minyak, gas, dan batubara mencapai 13,0x. Rentang PER perusahaan sejenis berada pada kisaran 12,2x hingga 13,0x dalam 5 tahun terakhir. Berdasar valuasi dengan pendekatan *discounted cash flows* menggunakan nilai *weighted average cost of capital* (WACC) dan *perpetual growth rate* masing-masing sebesar 9,80% dan 2,50%, diestimasi bahwa nilai ekuitas saham MEDC berada pada Rp7.634,00 per saham. Dapat disimpulkan bahwa saham MEDC masih *undervalued*.

PT Medco Energi Internasional Tbk

BALANCE SHEETS

in US\$mn	2023A	2024A	(Q2) 2025A	2025E	2026F
Assets					
Cash	353.9	637.0	824.3	1,124.8	1,625.1
Short Term Investment	11.0	11.0	11.0	11.0	11.0
Restricted Funds	70.8	60.4	58.2	60.4	60.4
Short Term AR	608.2	622.2	847.6	711.2	784.1
Inventories	126.8	156.1	155.7	146.4	161.4
Prepaid Expenses	16.5	11.8	15.2	18.5	20.4
Other CA	359.5	318.3	192.4	318.3	318.3
Total CA	1,546.6	1,817.0	2,104.5	2,390.7	2,980.8
Fixed Assets	3,400.7	3,258.3	3,156.7	3,258.3	3,258.3
Long Term Investments	1,653.0	1,819.8	1,758.9	1,819.8	1,819.8
Long Term AR	141.4	135.8	170.8	135.8	135.8
Restricted Funds	.1	-	-	-	-
Goodwill	39.1	39.1	39.1	39.1	39.1
Other NCA	687.5	856.9	843.4	856.9	856.9
Total NCA	5,921.7	6,109.9	5,968.8	6,109.9	6,109.9
Total Assets	7,468.3	7,926.9	8,073.3	8,500.7	9,090.7
Liabilities					
Short Term Bank Loan	147.6	54.7	15.0	15.0	15.0
Current Portion of LTL	371.7	504.4	408.0	408.0	408.0
Short Term AP	405.0	490.9	522.1	436.9	481.6
Accrued Expenses	240.0	276.1	303.5	279.8	308.5
Other CL	257.8	179.4	217.5	179.4	179.4
Total CL	1,422.1	1,505.4	1,466.0	1,319.0	1,392.5
Long Term Loans	3,014.6	3,018.9	3,312.9	3,312.9	3,312.9
Deferred Tax Liabilities	731.0	686.5	647.7	686.5	686.5
Provision for Retirement Benefits	31.5	35.6	41.2	35.6	35.6
Other NCL	241.6	329.5	300.9	329.5	329.5
Total NCL	4,018.7	4,070.5	4,302.6	4,364.5	4,364.5
Total Liabilities	5,440.7	5,575.9	5,768.6	5,683.5	5,757.0
Equity					
Common Stock	121.8	121.8	121.8	121.8	121.8
Additional Paid-In Capital	496.2	498.1	476.3	498.1	498.1
Treasure Stock	.5	.3	2.2	.3	.3
Retained Earning	1,211.0	1,499.2	1,475.3	1,964.6	2,481.2
Non-Controlling Interest	199.1	232.3	233.5	232.3	232.3
Total Equity	2,027.6	2,351.0	2,304.7	2,817.2	3,333.8
Total Equity and Liability	7,468.3	7,926.9	8,073.3	8,500.7	9,090.7

Source: Company. IDX

PT Medco Energi Internasional Tbk

INCOME STATEMENT

in US\$mn	2023A	2024A	(Q2) 2025A	2025E	2026F
Revenue	2,249.3	2,399.2	1,138.4	2,645.1	2,916.2
Cost of Revenue	1,215.7	1,465.7	702.6	1,481.9	1,633.7
Gross Profit	1,033.7	933.5	435.8	1,163.3	1,282.5
Operational Expenses	(241.4)	(216.9)	(98.0)	(283.8)	(312.9)
Operating Profit	792.3	716.6	337.8	879.4	969.6
Other Income (Expenses)	(64.4)	(45.5)	(155.3)	(6.4)	(.9)
EBT	727.9	671.1	182.5	873.0	968.7
Income Tax Expenses	(339.7)	(289.3)	(139.9)	(407.4)	(452.0)
Income (Loss) from Discontinued Operation	(42.4)	(1.5)	(.2)	(.2)	(.0)
EAT	345.8	380.2	42.4	465.4	516.6

Source: Company. IDX

CASH FLOWS

in US\$mn	2023A	2024A	(Q2) 2025A	2025E	2026F
CF from operating act.	1,116.4	723.2	1,219.5	329.9	500.2
CF from investing act.	(1,063.0)	(629.3)	(369.0)	-	-
CF from financing act.	64.4	(346.6)	(569.2)	157.9	-
Change in cash flow	117.9	(252.7)	281.4	487.8	500.2
Exchange rate changes	4.1	(3.2)	(2.2)	-	-
CF from other act.	(3.0)	9.8	3.9	-	-
CF at the beginning of year	481.0	600.0	353.9	637.0	1,124.8
CF at the end of year	600.0	353.9	637.0	1,124.8	1,625.1

Source: Company. IDX

RATIOS

in US\$mn	2023A	2024A	(Q2) 2025A	2025E	2026F
Liquidity Ratios					
Current Ratio	1.1	1.2	1.4	1.8	2.1
Quick Ratio	.7	.8	1.1	1.4	1.7
Cash Ratio	.2	.4	.6	.9	1.2
Turnover Ratios					
Asset Turnover	.3	.3	.1	.3	.3
Fixed Asset Turnover	.7	.7	.4	.8	.9
Equity Turnover	1.2	1.0	1.0	.4	.9
Profitability Ratios					
Gross Profit Margin	.5	.4	.4	.4	.4
Operating Profit Margin	.4	.3	.3	.3	.3
Net Profit Margin (NPM)	.2	.2	.0	.2	.2
ROE	.2	.2	.0	.2	.2
ROA	.0	.0	.0	.1	.1
Solvency Ratios					
Debt/Equity	1.7	1.5	1.6	1.3	1.1
Long Term Debt/Equity	1.5	1.3	1.4	1.2	1.0
Current Liability/Equity	.7	.6	.6	.5	.4
Debt/Total Asset	.5	.5	.5	.4	.4
Financial Leverage	3.8	3.5	3.4	3.2	2.9

Source: Company. IDX

PROFINDO Research Team

Darmawan Putra Wijaya
(Research Analyst)
darmawan.putra@profindo.com
Ext. 137

Lies Lilia Jamin
(Research Analyst)
liesljamin@profindo.com
Ext. 180

Setya Pambudi
(Research Analyst)
setya.pambudi@profindo.com
Ext. 181

PROFINDO Equity Sales Team

Alvian Satria
(OLT and Marketing)
alvian.satria@profindo
Ext. 111

HEAD OFFICE

Permata Kuningan Building, 19F
Jl. Kuningan Mulia, Kav. 9C, Guntur Setiabudi
South Jakarta 12980
Phone : +62 21 5093 1888
Fax : +62 21 5093 1889
WA (Helpdesk) : +62 811 8747 088
WA (Research) : +62 811 1098 378
Instagram : @profindosekuritas
Facebook : ProclikProfindo
Tiktok : @profindosekuritas

BRANCH OFFICE

SERANG

IDX Indonesia Stock Exchange
Jl. Veteran No 39-40
Cimuncang, Kota Serang
Banten 42117

DISCLAIMER

This research report is prepared by PT PROFINDO SEKURITAS INDONESIA for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. The report has been prepared without regard to individual financial circumstance, need or objective of person to receive it. The securities discussed in this report may not be suitable for all investors. The appropriateness of any particular investment or strategy whether opined on or referred to in this report or otherwise will depend on an investor's individual circumstance and objective and should be independently evaluated and confirmed by such investor, and, if appropriate, with his professional advisers independently before adoption or implementation (either as is or varied).